|Title:||Epidemiology of complementary and alternative medicine therapy use in allogeneic hematopoietic stem cell transplant survivorship patients in Australia|
efficacy and safety
allogeneic hematopoietic stem cell transplant (HSCT) survivors
complementary and alternative medical therapies (CAM)
stem cell transplantation.
|Citation:||Lindsay, J., Kabir, M., Gilroy, N., Dyer, G., Brice, L., Moore, J., Greenwood, M., Hertzberg, M., Gottlieb, D., Larsen, S. R., Hogg, M., Brown, L., Huang, G., Tan, J., Ward, C. and Kerridge, I. (2016), Epidemiology of complementary and alternative medicine therapy use in allogeneic hematopoietic stem cell transplant survivorship patients in Australia. Cancer Med. doi:10.1002/cam4.889. Published online 27 Oct 2016|
|Abstract:||In addition to prescribed conventional medicines, many allogeneic hematopoietic stem cell transplant (HSCT) survivors also use complementary and alternative medical therapies (CAM), however, the frequency and types of CAMs used by allogeneic HSCT survivors remain unclear. Study participants were adults who had undergone an allogeneic HSCT between 1st January 2000 and 31st December 2012. Participants completed a 402-item questionnaire regarding the use of CAM, medical complications, specialist referrals, medications and therapies, infections, vaccinations, cancer screening, lifestyle, and occupational issues and relationship status following stem cell transplantation. A total of 1475 allogeneic HSCT were performed in the study period. Of the 669 recipients known to be alive at study sampling, 583 were contactable and were sent study packs. Of 432 participants who returned the completed survey (66% of total eligible, 76% of those contacted), 239 (54.1%) HSCT survivors used at least one form of CAM. These included dietary modification (13.6%), vitamin therapy (30%), spiritual or mind–body therapy (17.2%), herbal supplements (13.5%), manipulative and body-based therapies (26%), Chinese medicine (3.5%), reiki (3%), and homeopathy (3%). These results definitively demonstrate that a large proportion of HSCT survivors are using one or more form of CAM therapy. Given the potential benefits demonstrated by small studies of specific CAM therapies in this patient group, as well as clearly documented therapies with no benefit or even toxicity, this result shows there is a large unmet need for additional studies to ascertain efficacy and safety of CAM therapies in this growing population.|
|Type of Work:||Article|
|Appears in Collections:||Research Papers and Publications. Sydney Health Ethics|
|Lindsay_et_al-2016-Cancer_Medicine.pdf||74.57 kB||Adobe PDF|
Items in Sydney eScholarship Repository are protected by copyright, with all rights reserved, unless otherwise indicated.